Institut Pasteur

Other

Centre National De La Recherche Scientifique

Yeda Research and Develpment & Co. Ltd

Institut National De La Sante Et De La Recherche Medicale

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Institut Pasteur and Centre National De La Recherche Scientifique

Inst. Nat'l De La Sante Et Recherche

Pierre Tiollais

Anne Dejean

Agnes Marchio

Luc Montagnier

Pierre Sonigo

Marc Alizon

Simon Wain-Hobson

Jean-Claude Chermann

Michel Revel

Francoise Barre Sinoussi

Patrick Charnay

Christine Pourcel

Pierre H Chambon

Martin Petkovich

Nigel Brand

Andree Krust

Hugues Blaudin De The

Robert C Gallo

Michel Perricaudet

Stewart T Cole

Solange Chamaret

Francoise Barre-Sinoussi

Christine Rouzioux

Mangalasseril G Sarngadharan

Mikulas Popovic

Francoise Rey

Willy Rozenbaum

Claudine Axler-Blin

Charles Dauguet

Oliver Danos

Marie-Louise Michel

Marie-Therese Nugeyre

Rolf E Streeck

Charles Chany

Francis Galibert

Jacques Gruest, Legal Representative

Annick Ballay

Francois Brun-Vezinet

Alex Fritsch

Yves Malpiece, Deceased

Hughes Blaudin De The

Massimo Levredo

Anne Louise

Francois Clavel

Denise Guetard

Mireille Guyader

Hisaki Nagai

Pascal Pineau

Marie-Annick Buendia

Marie-Francedillaoise Dubois

Anne DeJean

Marie-Francoise Dubois

Eliane Sobczak

Hughes B De The

Elaine Sobczak

Francois Galibert

Lisa Chakrabarti

This invention is in the field of lymphadenopathy virus. This invention relates to a diagnostic means and method to detect the presence of DNA, RNA, or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them, and the proteins expressed.

Nucleic acid probe of human immunodeficiency virus type 1 (HIV-1), and a method and kit employing this probe for detecting the presence of nucleic acid of HIV-1

This invention is in the field of lymphadenopathy virus. This invention relates to a diagnostic means and method of detecting lymphadenopathy associated virus or related viruses or DNA pro-viruses with cloned DNA sequences which are hybridizable to genomic RNA and DNA of lymphadenopathy associated virus. It further relates to the cloned DNA sequences and a process for their preparation.

Cloned DNA sequences hybridizable with genomic RNA of lymphadenopathy associated virus (LAV)

The inventors have isolated cloned cDNA encoding the RNA genome of Human Immunodeficiency Virus type 1 (HIV-1). Various clones are described, which encode different regions of the genome, including those regions encoding viral antigens or proteins. Hybridization results indicate the difference between the HIV-1 clones and those of HTLV-I and HTLV-II. The inventors have also produced a restriction map of the entire cloned genomic sequence in order to facilitate further subcloning and using the restriction fragments in other hybridization tests and in methods to express encoded sequences.

HIV-1 DNA fragments that hybridize to genomic HIV-1DNA

A method for identifying a synthetic ligand for retinoic acid receptor &#x3b2; comprises providing a sample, including a synthetic compound, exposing the sample to cultured cells, wherein the cultured cells comprise RAR&#x3b2;, determining if transcriptional expression of a gene encoding RAR&#x3b2; is upregulated compared to transcriptional expression of a control gene, and choosing a sample that upregulates the expression of RAR&#x3b2; as being a synthetic ligand for RAR&#x3b2;.

Identification of a synthetic ligand for retinoic acid receptor beta

Method for detecting human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) activity

This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1) to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates tot he DNA fragments, vectors comprising them and the proteins expressed.

DNA sequence of the LTR region of human immunodeficiency virus type 1 (HIV-1)

This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.

Cloned DNA sequence related to genomic RNA of human immunodeficiency virus (HIV-1)

Recombinant DNA modified by a nucleotide sequence coding for a specific polypeptide sequence whose expression is sought, this recombinant DNA being appropriate to the transformation of eucaryotic cell lines, notably human or animal, the endogenous polymerases of which are susceptible of recognizing the adenovirus promoters. The DNA according to the invention is more particularly characterized by the fact that the said insertion nucleotide sequence is placed under the direct control of the early promoter of the E1A region of the genome of adenovirus.

Adenoviral vector with a deletion in the E1A coding region expressing a hetorologous protein

A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA library. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone receptors. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all nonhepactic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap protein and as a probe in the detection and isolation of complementary DNA and RNA sequences. The hap protein is a retinoic acid (RA) receptor identified as RAR-&bgr;.

Steroid/thyroid hormone receptor-related gene which is inappropriately expressed in human hepatocellular carcinoma and which is a retinoic acid receptor

Defective recombinant adenovirus lacking E1A coding sequence and comprising a heterologous nucleotide sequence under control of the E1A promoter

A process produces DNA corresponding to that of the DNA of the virus of B hepatitis. It comprises cloning in bacteria the latter DNA, previously repaired by means of the corresponding precursor nucleotides in the presence of a polymerase. Vectors contain the cloned DNA in their genomes. The cloned DNA is useful as a probe for detecting the presence of the virus of B hepatitis in biological samples, particularly blood or plasma. Its expression in bacteria provides a hybrid protein containing a protein fragment having vaccinating properties against hepatitis B. Nucleic acid of reduced size and a vector containing the nucleotide sequence of which DNA codes an immunogenic peptide sequence capable of inducing the generation of antibodies to the virus of viral hepatitis B. It comprises totally or partly the sequence of nucleotides represented in FIG. 9A. Application to the production by cloning in a bacterium of an immunogenic protein immunizing against hepatitis B, or application to the obtention of probes for the diagnosis of the presence of Dane particles in the serum.

NUCLEOTIDE SEQUENCE COMPRISING THE GENOME OF HEPATITIS B VIRUS, NUCLEOTIDE SEQUENCE CODING THE SURFACE ANTIGEN OF THE HEPATITIS B VIRUS, VECTORS CONTAINING THE NUCLEOTIDE SEQUENCES, PROCESS FOR THE PREPARATION THEREOF, AND ANTIGEN OBTAINED THEREBY

The present invention pertains to new polynucleotides or new combinations of polynucleotides useful as diagnostic tools for predicting the occurrence of a human hepatocellular carcinoma disease. The invention is also directed to polynucleotides that consist in candidate tumor suppressor genes the alteration of which is involved in the occurrence of hepatocellular carcinoma in a patient, as well as to polynucleotides derived from such new candidate tumor suppressor genes and to the corresponding expressed polypeptides. The invention also concerns diagnostic methods using said polynucleotides as diagnostic tools.

Diagnostic means useful for predictive assessment of human hepatocellular carcinoma disease (HCC), as well as diagnostic methods using the same

The invention relates to a process for producing DNA corresponding to that of the DNA of the virus of B hepatitis. It comprises cloning in bacteria the latter DNA, previously repaired by means of the corresponding precursor nucleotides in the presence of a polymerase. The invention also relates to vectors containing said cloned DNA in their genomes. The cloned DNA is useful as a probe for detecting the presence of the virus of B hepatitis in biological samples, particularly blood or plasma. Its expression in bacteria provides a hybrid protein containing a protein fragment having vaccinating properties against hepatitis B.

Process for the production of DNA comprising the genome of the hepatitis B virus and vector including it

Nucleotide sequence comprising the genome of hepatitis B virus,

The invention concerns a composition useful for the manufacture of vaccines containing particles having the immunogenic properties characteristic of the antigen HBsAg, these particles being more particularly characterized by the fact that the particles equally contain a receptor for polymerized human albumin. They are obtained by transformation of human or animal cells by a vector containing a DNA sequence coding for the S and pre-S regions of a genome of viral hepatitis B, this DNA sequence being placed under the direct control of a promoter permitting the effective transcription of the sequence in the human or animal cells transformable by the vector.

Vectors for transforming CHO cells

Growing community of inventors

Paris, France

Pierre Tiollais